EGFR Inhibitor Synthesis Without Oxidizing Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for synthesizing tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one-containing chemical entities that inhibit EGFR and HER2 require the use of oxidizing agents, which are costly and pose safety concerns.
Innovation Solution
The synthesis of these chemical entities is improved by eliminating the need for oxidizing agents, such as peroxy acids, in the cyclization steps, thereby simplifying and safer scaling-up processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If oxidizing agents (e.g., peroxy acids) are used in cyclization steps, then the synthesis can proceed, but safety concerns and production costs increase
Solution Approach 1:
The patent removes the oxidizing agent step from the synthesis pathway by using an alternative cyclization method that proceeds without oxidation. This extraction of the harmful element (oxidizing agent) eliminates safety concerns while maintaining the desired chemical transformation.
Solution Approach 2:
The patent replaces expensive and hazardous oxidizing agents with a simpler, safer alternative reagent system that is less costly and eliminates the need for specialized safety protocols, thereby reducing production costs and improving ease of manufacture.
2Ease of manufacture
If oxidizing agents are used in cyclization steps, then the synthesis can proceed, but production costs increase
Solution Approach 1:
The patent replaces expensive oxidizing agents with cheaper alternative reagents that achieve the same cyclization transformation without requiring costly materials, thereby reducing production costs.
Solution Approach 2:
The patent eliminates the need to handle and dispose of hazardous oxidizing agents and their waste products, thereby reducing costs associated with safety equipment, waste disposal, and regulatory compliance.
3Ease of manufacture
If oxidizing agents are used in cyclization steps, then the synthesis can proceed, but safety concerns arise
Solution Approach 1:
The patent removes the oxidizing agent step from the synthesis pathway, thereby eliminating the safety hazards associated with handling, storing, and disposing of these hazardous chemicals while maintaining the desired chemical transformation.
Solution Approach 2:
The patent converts a potentially harmful oxidation process into a safer alternative cyclization reaction that achieves the same synthetic goal without generating hazardous intermediates or requiring specialized safety protocols.
Data Source
AI summary
This disclosure features methods for preparing tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one-containing chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that inhibit epidermal growth factor receptor (EGFR, ERBB 1) and/or Human epidermal growth factor receptor 2 (HER2, ERBB2) as well as synthetic intermediates useful for the preparation of said chemical entities. The methods include, for example, improved methods for synthesizing compounds of formula (I) as described herein.